Company: ARWR
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001628280-25-024666
Chunk: 46

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 46
---
 Plan2021 PlanInducement AwardsTotalGranted and outstanding awards:Options891,211 32,151 602,355 1,525,717 Restricted stock units1,500,000 3,939,734 494,009 5,933,743 Total2,391,211 3,971,885 1,096,364 7,459,460 The following table summarizes stock-based compensation expenses included in operating expenses:Three Months Ended March 31,Six Months Ended March 31,2025202420252024(in thousands)Research and development$7,264 $7,097 $14,110 $15,413 General and administrative7,817 9,491 15,147 18,860 Total$15,081 $16,588 $29,257 $34,273 Stock Option AwardsThe following table presents a summary of the stock option activity for the six months ended March 31, 2025:SharesWeighted-AverageExercisePricePer ShareWeighted-AverageRemainingContractualTerm (Years)AggregateIntrinsicValueOutstanding at September 30, 20241,978,516$23.39 Granted—— Cancelled or expired(30,466)43.12 Exercised(422,333)7.67 Outstanding at March 31, 20251,525,717$27.35 3.7$3,831,887 Exercisable at March 31, 20251,525,717$27.35 3.7$3,831,887 

17

The aggregate intrinsic values represent the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the three months ended March 31, 2025 and 2024 was $3.7 million and $2.5 million, respectively. The total intrinsic value of the options exercised during the six months ended March 31, 2025 and 2024 was $4.6 million and $3.1 million, respectively.Stock-based compensation expense related to stock options outstanding for the three months ended March 31, 2025 and 2024, was $3.0 thousand and $0.6 million, respectively. Stock-based compensation expense related to stock options outstanding for the six months ended March 31, 2025 and 2024, was $